Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Urinary Bladder Neoplasms 1Thymoma 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1SCLC, Extensive Stage 1Resectable Esophageal Cancer 1Rectal Neoplasms 1Pathologic Complete Response 1Oropharyngeal Neoplasms 1Neoplasms 1NSCLC 1Mouth Neoplasms 1Lung Neoplasms 1Esophageal Squamous Cell Carcinoma 1Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Etoposide 14Carboplatin 13Cisplatin 9anlotinib 8toripalimab 5PM 01183 5Drug Therapy 5tislelizumab 4Topotecan 4Radiotherapy 4Platinum 4irinotecan sucrosofate 3durvalumab 3atezolizumab 3famitinib 2apatinib 2Pemetrexed 2Paclitaxel 2surufatinib 1sintilimab 1osimertinib 1nintedanib 1fludarabine 1amrubicin 1Tomography, X-Ray Computed 1Tissue Banks 1Radiation Dose Hypofractionation 1Rabeprazole 1Proton Pump Inhibitors 1Platinum Compounds 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Small Cell Lung Carcinoma × Chemoradiotherapy × Clear all
NCT07200154 2025-09-30

Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC

Peking University Cancer Hospital & Institute

Phase 2 Not yet recruiting
30 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡